Conference Day One

Wednesday 28th August, 2024

8:00 am Check-In Opens & Light Breakfast

8:50 am Chair’s Opening Remarks

Optimising Different Techniques Used for Accurate mRNA Characterisation to Enhance Efficiency & Accuracy in Order to Achieve Robust Results

9:00 am Highlighting the Advancements in mRNA poly (A) tail Characterisation to Enhance Efficacy

  • Yurong Guo Senior Director - Analytical Development, Arcturus Therapeutics


  • Discussing the latest methods used to characterise the poly (A) tail to provide valuable information about the dynamics of mRNA regulation
  • Uncovering new insights into the mechanisms underlying protein expression of the mRNA to pave the way for more effective treatments for a wide range of diseases

9:30 am Introducing Advanced Biophysical Characterisation Methods to Quality Control of mRNA Pharmaceuticals


  • What are the advanced biophysical characterisation methods
  • What are the principles of biophysical techniques
  • How do you apply biophysical methods in assessing mRNA stability, structure, and purity

10:00 am Morning Break & Speed Networking


This session is your opportunity to get face-to-face time with many of the brightest minds working in the mRNA Analytical Development field, and establish meaningful business relationships to pursue for the rest of the conference.

Exploring How to Navigate the Fast-Changing mRNA Environment & Unveil Strategies to Align Your mRNA Vaccines with Regulatory Guidelines & Streamline Through to Approval

11:00 am Unlocking the Importance for Adaptability for Release Assays & Navigating the Regulatory Seas For The Development of Effective mRNA Vaccine

  • Philippe Talaga Global Head of Research Platforms, CMC Leaders & Experts, Sanofi


  • Could we consider the current mRNA vaccine regulatory landscape as foggy?
  • Emphasize the importance of adaptability in the context of fast changing environment
  • How can we differentiate the release and characterisation assays for mRNA vaccines?
  • Using Analytical Platform Technologies and life cycle management to support accelerated mRNA vaccines development

11:30 am Roundtable Discussion: How to Create a Reference Document to Facilitate Smooth Approval of mRNA Therapeutics in Compliance with Industry Regulations


  • Delving into how to give evidence of a state of control and maintain regulatory compliance for your mRNA analytical techniques
  • Unveiling strategies to incorporate innovative mRNA analytical technologies in alignment with GMP guidelines
  • Understanding the process of standardizing mRNA analytical techniques to conform to CQAs and CPIs, thereby enabling efficient and expeditious approval

12:30 pm Networking Lunch

Overcoming Production Hurdles for mRNA & siRNA Hurdles & Improve the Quality of Obtained mRNA Samples to Achieve High Purity Samples

1:30 pm Integrity Analysis of mRNA: Characterization of Break-off Transcripts & degradation Products


  • Molecular integrity of therapeutic mRNAs is essential for their functionality, and understanding of product-related impurities is important to ensure product quality. 
  • Approaches to analyze mRNA integrity by liquid-chromatography with UV and mass spectrometric detection will be presented.
  • Aim: Improve understanding of species derived from full-length mRNA

2:00 pm Roundtable Discussion: Innovations in Addressing dsRNA Challenges to Develop More Precise, Potent, & Safer mRNA Therapies


  • Understanding dsRNA ability to effectively target specific mRNA sequences, resulting in increased specificity and accuracy in mRNA analysis
  • Discussing the possible strategies to improve its specificity and reduce the potential for off-target effects
  • Addressing the regulatory hurdles in the use of dsRNA in mRNA analytical development to ensure safety and efficacy of these technologies

3:00 pm Afternoon Break & Poster Session


By joining our dedicated session, you will have the opportunity to engage in meaningful discussions with your peers about ongoing work in the field of mRNA analytical development. As the discovery and development of these therapies continues to advance, it is essential to collaborate and share knowledge to streamline the approval process. Share your latest findings and gain insight into the cutting edge work of your peers. The goal of this session is to foster a sense of community and promote collaboration within the field.

Enhancing Stability & Efficacy through Tail Sequence Analysis & Delve into Strategies for Addressing Capillary Electrophoresis Hurdles to Produce Safe & Effective mRNA Therapies

4:00 pm Optimising Tail Sequence Analysis for mRNA Therapeutics to Enhance Stability & Efficacy

  • Yi Kuang Assistant Professor, Hong Kong Science & Technology Parks


  • What are the methods for analysing and optimising tail sequences for mRNA stability and efficacy
  • What is the impact of tail sequence modifications on mRNA translation and function
  • What are the regulatory requirements and guidelines related to tail sequence optimisation

4:30 pm Exploring the Recent Advances in Capillary Electrophoresis & Their Impact on Analytical Chemistry to Streamline Development


  • Investigating the advantages of using capillary electrophoresis over current methods to get high sensitivity and the ability to analyze samples with low volumes
  • Discussing the development of new analytical methods for the characterisation of interactions between antigens and adjuvants in vaccines by capillary electrophoresis
  • Reviewing what is in store for the future of capillary electrophoresis and its potential for speeding up analytical methods

5:00 pm End of Conference Day One